Abstract
To assess the ability of intranasal atipamezole to reverse sedative effects of xylazine in dogs. Prospective proof-of-concept study. University research laboratory. Six healthy, staff-owned dogs. Dogs were sedated with 1.1mg/kg of xylazine intravenously. The sedation score of each dog was recorded every 5minutes until they achieved a sedation score of >13/21 for 3 readings. Once achieved, 0.3mg/kg of atipamezole was administered intranasally using a mucosal atomization device. Sedation scores continued to be recorded every 5minutes until successful reversal was achieved (<4/21). Average times to standing and normal wakefulness after administration of intranasal atipamezole were 6minutes, 30seconds and 7minutes, 20seconds, respectively. Intranasal atipamezole successfully reversed the sedation effects of xylazine. The findings of this study provide justification for future controlled prospective studies into the potential use of intranasal atipamezole in a variety of settings including exposure to xylazine in operational canines as well as bioavailability studies for optimal dosing.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
